Having trouble accessing articles? Reset your cache.

PDL BioPharma, Roche cancer, ophthalmic, inflammation news

PDL said it received a letter on Aug. 11 from Genentech Inc. asserting that four of the Roche unit's products do not infringe

Read the full 234 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE